ATE173016T1 - Von tat abgeleitete transportpolypeptide - Google Patents

Von tat abgeleitete transportpolypeptide

Info

Publication number
ATE173016T1
ATE173016T1 AT93920231T AT93920231T ATE173016T1 AT E173016 T1 ATE173016 T1 AT E173016T1 AT 93920231 T AT93920231 T AT 93920231T AT 93920231 T AT93920231 T AT 93920231T AT E173016 T1 ATE173016 T1 AT E173016T1
Authority
AT
Austria
Prior art keywords
tat
transport polypeptides
absence
polypeptides
amino acids
Prior art date
Application number
AT93920231T
Other languages
English (en)
Inventor
James G Barsoum
Stephen E Fawell
R Blake Pepinsky
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ATE173016T1 publication Critical patent/ATE173016T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
AT93920231T 1992-08-21 1993-08-19 Von tat abgeleitete transportpolypeptide ATE173016T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93437592A 1992-08-21 1992-08-21

Publications (1)

Publication Number Publication Date
ATE173016T1 true ATE173016T1 (de) 1998-11-15

Family

ID=25465458

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93920231T ATE173016T1 (de) 1992-08-21 1993-08-19 Von tat abgeleitete transportpolypeptide

Country Status (14)

Country Link
EP (3) EP0656950B1 (de)
JP (2) JP2702285B2 (de)
KR (1) KR0153027B1 (de)
AT (1) ATE173016T1 (de)
AU (1) AU667244B2 (de)
CA (1) CA2135642C (de)
DE (2) DE69321962T2 (de)
DK (1) DK0656950T3 (de)
ES (1) ES2123062T3 (de)
FI (1) FI120495B (de)
HK (1) HK1012678A1 (de)
NO (1) NO316761B1 (de)
NZ (1) NZ255831A (de)
WO (1) WO1994004686A1 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219990A (en) * 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
US5861161A (en) * 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US5955593A (en) * 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US6623938B2 (en) * 1997-01-21 2003-09-23 Human Genome Sciences, Inc. I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95 induced apoptosis
ATE251913T1 (de) 1997-05-21 2003-11-15 Univ Leland Stanford Junior Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen
CA2291483C (en) 1997-06-06 2012-09-18 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
US7306784B2 (en) 1998-06-20 2007-12-11 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
JP2002518521A (ja) 1998-06-20 2002-06-25 ワシントン・ユニバーシティ 医用画像解析、診断および治療のための膜透過性ペプチド錯体
JP2004513059A (ja) * 1998-12-24 2004-04-30 ユセベ，ソシエテ　アノニム ペプチド産物、方法及び組成物
DE19916224C1 (de) * 1999-04-10 2000-06-21 November Ag Molekulare Medizin Synthetisches biologisch aktives Molekül
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
AU769315B2 (en) 1999-08-24 2004-01-22 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
AU7473500A (en) * 1999-09-01 2001-03-26 University Of Pittsburgh Identification of peptides that facilitate uptake and cytoplasmic and/or nucleartransport of proteins, dna and viruses
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2001049832A2 (en) * 2000-01-07 2001-07-12 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
DK2364734T3 (en) 2000-07-21 2017-10-30 Revance Therapeutics Inc Biological multicomponent transport systems
KR100379577B1 (ko) * 2000-07-26 2003-04-08 최수영 세포침투성 티에이티 - 인간 글루탐산 탈수소효소 융합단백질, 이 융합단백질을 코딩하는 재조합폴리뉴클레오타이드, 이 융합단백질의 발현벡터 및 이융합단백질을 세포 내로 도입하는 방법
KR100379578B1 (ko) * 2000-07-26 2003-04-08 최수영 세포침투성 티에이티-씨3 트랜스페라제 융합단백질, 이융합단백질의 발현벡터 및 티에이티-씨3 트랜스페라제를이용한 로 단백질의 생리적 기능 분석방법
EP1332209B1 (de) 2000-09-08 2009-11-11 Universität Zürich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US20050059031A1 (en) * 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
US7585834B2 (en) 2001-02-16 2009-09-08 The Board Of Trustees Of The Leland Stanford Junior University Transporters comprising spaced arginine moieties
DE60232443D1 (de) * 2001-06-05 2009-07-09 Masahiro Hiraoka Polypeptid-destabiliserendes protein in zellen unter aeroben bedingungen und dieses codierende dna
KR100495138B1 (ko) * 2001-07-31 2005-06-14 학교법인 한림대학교 식물세포 투과 도메인-화물분자 복합체
ATE509120T1 (de) 2001-09-18 2011-05-15 Carnegie Inst Of Washington Fusionsproteine zur detektion von analyten
EP1436315A2 (de) * 2001-10-19 2004-07-14 The Scripps Research Institute Neue verfahren zum einschleusen von molekülen in zellen, und vektoren und zusammensetzungen für die verwendung bei diesen verfahren
US7635681B2 (en) 2002-01-09 2009-12-22 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7026166B2 (en) 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
EP1354953A1 (de) * 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-Peptide zur Verwendung als therapeutische Mittel gegen Krebs und Autoimmunerkrankungen
EP1495124A2 (de) * 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptide zur verwendung als therapeutische mittel gegen krebs und autoimmunerkrankungen
EP2332559A1 (de) 2002-04-22 2011-06-15 The Board Of Trustees Of The Leland Stanford Junior University Peptide zur Behandlung von Schmerzen
KR100472939B1 (ko) * 2002-05-24 2005-03-18 학교법인 한림대학교 세포침투성 티에이티-피리독살 카이네이즈 융합단백질 및그 용도
WO2004009666A2 (en) 2002-07-19 2004-01-29 The Regents Of The University Of California Dendrimers as molecular translocators
KR100472938B1 (ko) * 2002-10-31 2005-03-11 학교법인 한림대학교 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
CA2523672C (en) 2003-04-29 2012-07-17 Avi Biopharma, Inc. Compositions for enhancing transport of molecules into cells
WO2005035562A1 (ja) * 2003-10-07 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. 新規な細胞増殖促進剤
EP1706423B8 (de) 2003-12-05 2009-07-08 multimmune GmbH Therapeutische und diagnostische anti-hsp 70-antikörper
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
AU2005251676B2 (en) 2004-03-03 2011-09-29 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
JP4474264B2 (ja) * 2004-08-20 2010-06-02 生寶生物科技股▲ふん▼有限公司 子宮頸癌抑制の融合蛋白
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
JP4596391B2 (ja) 2005-02-10 2010-12-08 国立大学法人大阪大学 細胞透過性ペプチド
DK1988167T3 (da) 2005-02-17 2020-07-13 Univ Sorbonne Intracellulære inhiberende peptider
ATE507236T1 (de) 2005-03-03 2011-05-15 Revance Therapeutics Inc Zusammensetzungen und methoden zur topischen anwendung und zur transdermalen verabreichung eines oligopeptids
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8258258B2 (en) 2005-03-10 2012-09-04 Biontech Ag Dimeric or multimeric microproteins
KR100699279B1 (ko) 2005-04-28 2007-03-23 학교법인 포항공과대학교 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법
US7973084B2 (en) 2005-04-28 2011-07-05 Postech Academy-Industrial Foundation Molecular transporters based on alditol or inositol and processes for the preparation thereof
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8883507B2 (en) 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
US7517959B2 (en) 2005-11-11 2009-04-14 Walter And Eliza Hall Institute Of Medical Research SOCS3 proteins
CN103408661B (zh) 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
AU2008224950B2 (en) 2007-03-13 2013-10-03 National Jewish Medical And Research Center Methods for generation of antibodies
MX2009009926A (es) 2007-03-13 2010-03-15 Univ Zuerich Anticuerpo tumor-especifico humano monoclonal.
US20110038865A1 (en) 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
ES2805225T3 (es) 2007-07-26 2021-02-11 Revance Therapeutics Inc Péptidos antimicrobianos y composiciones de los mismos
EP2185592B1 (de) 2007-09-13 2013-01-23 University Of Zurich Prorektorat Forschung Monoklonaler amyloid-beta (abeta)-spezifischer antikörper und seine verwendung
US7935816B2 (en) 2007-10-25 2011-05-03 Gene Tools, Llc Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
ES2671024T3 (es) 2008-02-28 2018-06-04 Toray Industries, Inc. Composición farmacéutica para administración transnasal
IL287311B1 (en) 2008-05-16 2024-02-01 Taiga Biotechnologies Inc Antibodies and processes for their preparation
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
ES2525411T3 (es) 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
EP2324044A4 (de) 2008-08-04 2012-04-25 Univ Miami Sting (stimulator von interferongenen) als regulator angeborener immunreaktionen
EP2966084B1 (de) 2008-08-28 2018-04-25 Taiga Biotechnologies, Inc. Myc-modulatoren, verfahren zur verwendung davon und verfahren zur identifikation von mitteln zur myc-modulierung
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
CA2762551C (en) 2009-05-20 2016-11-22 Toray Industries, Inc. Cell-penetrating peptides
CA2780741C (en) 2009-10-12 2023-04-04 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2849382C (en) * 2010-09-22 2021-02-16 The Regents Of The University Of Colorado, A Body Corporate Therapeutic applications of smad7 for the treatment of oral mucositis
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
CN103347898B (zh) 2011-01-10 2017-12-05 Ct大西洋有限公司 包括与肿瘤相关抗原结合抗体的联合治疗
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
KR102339196B1 (ko) 2011-05-05 2021-12-15 사렙타 쎄러퓨틱스, 인코퍼레이티드 펩타이드 올리고뉴클레오타이드 접합체
JP2014524891A (ja) 2011-06-03 2014-09-25 シーティー アトランティック リミテッド Ｍａｇｅａ３結合抗体
JP2014518889A (ja) 2011-06-03 2014-08-07 シーティー アトランティック リミテッド Ｍａｇｅａ３結合抗体
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2013093122A2 (en) 2011-12-23 2013-06-27 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
HUE037186T2 (hu) 2011-12-28 2018-08-28 Immunoqure Ag Eljárás humán antitestek izolálására
CN114645015A (zh) 2012-07-20 2022-06-21 泰加生物工艺学公司 造血区室的增强的重建和自动重建
US9422352B2 (en) 2013-03-08 2016-08-23 The Regents Of The University Of Colorado, A Body Corporate PTD-SMAD7 therapeutics
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
EP2968613B1 (de) 2013-03-11 2019-09-11 University of Florida Research Foundation, Inc. Freisetzung von card-protein zur behandlung von augenentzündungen
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
EA201501080A1 (ru) 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CN112358548A (zh) 2013-07-03 2021-02-12 因美诺克股份公司 人抗IFN-α抗体、IFN-α结合片段、多核苷酸、组合物、试剂盒及应用和制备方法
WO2015138628A1 (en) 2014-03-11 2015-09-17 University Of Florida Research Foundation, Inc. Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
JP6468722B2 (ja) * 2014-04-30 2019-02-13 日本信号株式会社 物体検出装置
NZ737400A (en) 2015-06-01 2019-09-27 Medigene Immunotherapies Gmbh T cell receptor library
KR20180020202A (ko) 2015-06-01 2018-02-27 메디진 이뮤노테라피스 게엠바하 T 세포 수용체 특이적 항체
WO2016193300A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
JP6864364B2 (ja) 2015-06-11 2021-04-28 学校法人慶應義塾 融合タンパク質又は複合タンパク質、細胞内送達用担体、部分ペプチド、細胞膜透過促進剤、ｄｎａ、及びベクター
CA3009542C (en) 2015-12-23 2023-08-29 Medigene Immunotherapies Gmbh Novel generation of antigen-specific tcrs
US10583156B2 (en) 2016-12-02 2020-03-10 Taiga Biotechnologies, Inc. Nanoparticle formulations
BR112019012647A2 (pt) 2016-12-19 2019-11-19 Sarepta Therapeutics Inc conjugados de oligômero de salto de éxon para distrofia muscular
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
JPWO2020066343A1 (ja) 2018-09-26 2021-08-30 株式会社カネカ 細胞膜透過性ペプチド
WO2022154079A1 (ja) * 2021-01-18 2022-07-21 国立研究開発法人産業技術総合研究所 タンパク質を動物細胞に導入する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2091916T3 (es) * 1989-12-21 1996-11-16 Whitehead Biomedical Inst Metodo para suministrar moleculas en el interior de celulas eucarioticas.
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors

Also Published As

Publication number Publication date
EP0656950A1 (de) 1995-06-14
AU667244B2 (en) 1996-03-14
JP2702285B2 (ja) 1998-01-21
NO944273L (no) 1995-02-17
JP2869396B2 (ja) 1999-03-10
EP2000536A2 (de) 2008-12-10
KR0153027B1 (en) 1998-10-15
EP2000536A3 (de) 2010-06-30
CA2135642C (en) 1999-12-14
AU5083293A (en) 1994-03-15
JPH1033186A (ja) 1998-02-10
FI120495B (fi) 2009-11-13
DE656950T1 (de) 1996-03-14
CA2135642A1 (en) 1994-03-03
JPH07503617A (ja) 1995-04-20
NO316761B1 (no) 2004-05-03
EP0903408A3 (de) 2005-11-02
NO944273D0 (no) 1994-11-09
HK1012678A1 (en) 1999-08-06
NZ255831A (en) 1997-04-24
EP0656950B1 (de) 1998-11-04
DE69321962D1 (de) 1998-12-10
ES2123062T3 (es) 1999-01-01
DE69321962T2 (de) 1999-07-01
WO1994004686A1 (en) 1994-03-03
FI945248A (fi) 1995-01-05
DK0656950T3 (da) 1999-07-19
EP0903408A2 (de) 1999-03-24
FI945248A0 (fi) 1994-11-08

Similar Documents

Publication Publication Date Title
ATE173016T1 (de) Von tat abgeleitete transportpolypeptide
GB9720054D0 (en) Biological products
FI913637A0 (fi) Foer epitelceller specifik dna kodande vaextfaktor.
ATE256186T1 (de) Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
ES2103266T3 (es) Procedimiento de dna recombinante y celulas huesped.
ATE199377T1 (de) Protein mit cytokinaktivität, rekombinant-dns, expressionsvektor und wirtszellen zu seiner herstellung
Staros et al. Cross-linking and chymotryptic digestion of the extractoplasmic domain of the anion exchange channel in intact human erythrocytes
ATE197611T1 (de) Screeningverfahren von morphogenischen proteinen
ES2240971T3 (es) Genes supresores de tumores, proteinas codificadas por ellos y uso de dichos genes y proteinas.
Carsten Tropomyosin from smooth muscle of the uterus
DE3273606D1 (en) Process for the purification or concentration of biologically active proteins, and appropriate means therefor
ATE214708T1 (de) Kationische mittel zur transfektion von nukleinsäuren
ITRM920506A1 (it) Regioni antigeniche dei complessi tpl e anticorpi diretti contro di essi.
ATE143974T1 (de) Peptide des hiv-gag proteins, ihre herstellung und verwendung
Weber et al. Modifications of bovine prothrombin fragment 1 in the presence and absence of Ca (II) ions. Loss of positive cooperativity in Ca (II) ion binding for the modified proteins.
ATE205538T1 (de) Genregulatorische sequenzen von cd4, welche spezifisch in reifen t-zellen exprimiert werden
DE69533545D1 (de) Faltende proteine
許奎晶 Small GTP-binding Proteins
Perraudin et al. Disulfide content of reduced hen egg white and human milk lysozymes during the folding process
Tyndall Effect of TGF-beta superfamily members on limb mesenchymal chondrogenesis in vitro: Modulation of N-cadherin and catenin expression and association.
PT97820A (pt) Processo de obtencao de proteina map2-quinases, de microorganismos e linhas de celulas compreendendo moleculas recombinantes de map2-quinase e de detencao da presenca de actividade de factores celulares
KR950023648A (ko) 생물학적 활성을 나타내는 폴리펩티드
TH23717A (th) ธรอมโบพอยเอติน
DE3888078T2 (de) Veränderungsverfahren für Peptide und Proteine.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification